Treece Medical (TMCI) Q1 2025: New Bunion Systems to Target Remaining 75% of Surgeon Cases
Treece Medical’s Q1 marks an inflection as three new bunion systems position the company to address nearly all surgeon case preferences, setting up for a back-half growth acceleration. Management’s conviction in the expanded portfolio is clear, while operational discipline continues to drive EBITDA improvement. Investors should watch new product adoption and the Q3-Q4 ramp as the defining levers for 2025 trajectory.
Summary
- Portfolio Expansion Unlocks Market: Three new systems allow Treece to address almost all bunion procedure types.
- Operational Leverage Takes Hold: Expense management and EBITDA improvement continue for the third straight quarter.
- Back-Half Growth Is Critical: Full-year outlook hinges on successful Q3-Q4 product launches and surgeon adoption.
Performance Analysis
Treece Medical delivered Q1 revenue growth of 3%, or 4.5% adjusted for one less selling day, driven mainly by increased bunion procedure kit sales. Gross margin remained robust at just under 80%, while cost discipline led to a reduction in operating expenses year over year. The company’s adjusted EBITDA loss improved by 54% versus the prior year, marking a third consecutive quarter of progress toward breakeven. Cash and marketable securities ended at $76.1 million, with total liquidity of $98.6 million including revolver access, supporting ongoing R&D and commercial expansion.
Growth in Q1 was in line with expectations given a difficult comp and limited new product availability, with the company reiterating its full-year revenue guidance of 7% to 10% growth. Notably, management signaled that the most substantial revenue acceleration will occur in Q4, coinciding with full commercial availability of the new bunion systems and seasonal strength tied to patient deductible timing. The company’s ability to maintain gross margin and improve EBITDA despite ongoing investment in R&D and commercial buildout reflects a maturing operating model.
- Expense Control Drives Margin Resilience: Operating expenses fell below prior-year levels, supporting EBITDA improvement.
- Kit Sales Remain Core Revenue Driver: Bunion procedure kits continue as the primary revenue source ahead of portfolio expansion.
- Liquidity Remains Ample: Balance sheet strength supports continued investment in innovation and sales force expansion.
Investors should note that Q2 growth is expected to remain modest, with the real inflection tied to Q3-Q4 as new systems ramp.
Executive Commentary
"With the upcoming commercialization of three new best-in-class bunion correction systems... we gain more immediate and more targeted access to the remaining 75% of our surgeons' cases. So beginning in Q3, we have the opportunity to target virtually 100% of surgeon and patient preferences for bunion correction with five best-in-class instrumented systems addressing all four classes of bunion deformities."
John Treese, Chief Executive Officer
"Adjusted EBITDA loss for the first quarter was $3.8 million compared to $8.3 million in the first quarter of 2024, an improvement of 54%. This marks our third consecutive quarter of adjusted EBITDA improvements and represents significant progress toward our improved profitability goals of 2025."
Mark Hare, Chief Financial Officer
Strategic Positioning
1. Portfolio Expansion to Comprehensive Bunion Solutions
Treece is executing on a decade-long strategy to evolve from a single-technology company into a comprehensive bunion solutions provider. With the launch of nanoplasty, percuplasty 3D MIS osteotomy, and speed MTP fusion systems in Q3, Treece will address the full spectrum of bunion deformities and surgeon preferences. This shift positions the company to move beyond its historic 25% share of surgeon cases to potentially capture a much larger portion of the addressable market.
2. R&D and Innovation Pipeline
The company’s R&D engine is running at full throttle, with not only the three new systems but also complementary technologies like Intelliguide PSI (patient-specific pre-op planning), SpeedPlate MicroQuad (dynamic fixation for small incision fusion), and Speed Aiken (fixation for Aiken osteotomies). Treece also previewed a next-generation lapoplasty platform, “Lightning,” slated for limited release late in the year, which management describes as a “revolutionary advancement.”
3. Commercial Team and Market Access
Surgeon engagement and commercial team momentum are building, as evidenced by oversubscribed training labs and increased interest from experienced sales professionals. The expanded portfolio is expected to attract not only existing customers but also incremental new surgeons who favor osteotomy approaches, broadening the total addressable market (TAM).
4. Defending Leadership Amid Rising Competition
While competitive intensity remains high with lapoplasty “knockoffs” from multiline players, Treece’s focus and clinical data are cited as key differentiators. Management remains confident that its expanded, innovative suite will further separate Treece from competitors and support continued market leadership.
5. Operational Discipline and Profitability Focus
Expense management and operational efficiency remain priorities, with three straight quarters of EBITDA improvement and a goal of breakeven for 2025. Management is targeting a 50% reduction in cash burn for the year, even as it invests in R&D and commercial expansion.
Key Considerations
Treece’s Q1 sets the stage for a pivotal year, with the real test coming as new products reach full commercial scale and the company seeks to convert its expanded offering into accelerated revenue and margin improvement.
Key Considerations:
- Back-Half Launch Execution: The success of Q3-Q4 product rollouts will determine if Treece can capture the remaining 75% of surgeon bunion cases.
- Surgeon Adoption Curve: Oversubscribed training labs and positive early feedback are promising, but sustained utilization is the critical metric.
- Minimal Cannibalization Risk: Management expects new systems to address cases not previously captured, limiting cannibalization of lapoplasty volumes.
- Seasonality and Procedure Timing: Deferred elective procedures and deductible-driven seasonality create a back-half revenue bulge, amplifying launch risk and opportunity.
- Expense and Cash Management: Continued discipline is needed to achieve breakeven EBITDA and reduced cash burn, especially as commercial investments ramp.
Risks
Execution risk is elevated as Treece shifts from a single-product focus to a multi-system portfolio, with the full-year outlook hinging on the speed and breadth of new product adoption. Competitive pressure remains from larger players offering lapoplasty alternatives, and any delays in surgeon uptake or inventory ramp could pressure guidance. Seasonality and procedure deferrals also add unpredictability to quarterly pacing. Investors should watch for signs of slower-than-expected adoption or margin compression as the portfolio expands.
Forward Outlook
For Q2, Treece expects:
- Revenue growth consistent with Q2 2024 (~6%), reflecting limited new product impact and elective procedure timing.
For full-year 2025, management reaffirmed guidance:
- Revenue of $224 million to $230 million, or 7% to 10% growth.
- Breakeven adjusted EBITDA for the year.
- Cash burn reduction of approximately 50% versus 2024.
Management emphasized that the most substantial growth and margin improvement are expected in Q4, as new systems reach full commercial availability and seasonal demand peaks. Key drivers will be the pace of surgeon adoption and the ability to meet inventory and training needs at scale.
Takeaways
Treece’s 2025 trajectory hinges on the execution of its expanded bunion systems portfolio, with Q3-Q4 serving as the proving ground for both top-line acceleration and profitability gains.
- Portfolio Expansion Is the Growth Lever: The shift from 25% to near-total surgeon case coverage is a potential game-changer if adoption materializes as expected.
- Operational Efficiency Remains on Track: Three quarters of EBITDA improvement and expense discipline provide a margin of safety as investments increase.
- Q3-Q4 Ramp Is the Decisive Test: Investors should closely monitor new product utilization, surgeon training throughput, and sales force productivity as the year progresses.
Conclusion
Treece Medical enters a critical phase in 2025, with its expanded bunion solutions portfolio poised to unlock significant new market share. The company’s ability to deliver on back-half growth and profitability targets will define its long-term leadership in the bunion correction market. Investors should focus on execution and adoption metrics as the clearest signals of value creation this year.
Industry Read-Through
Treece’s aggressive move to a comprehensive, multi-system bunion platform reflects a broader medtech trend: companies are seeking to become one-stop procedural partners for surgeons, not just single-product vendors. The emphasis on surgeon training, patient-specific planning, and minimally invasive options signals where competitive differentiation is heading in orthopedics. For peers, the challenge is clear: depth of portfolio, clinical data, and commercial execution will determine share gains as elective procedure volumes rebound and surgeons seek more tailored solutions. Watch for similar portfolio expansions and training investments across the elective ortho landscape.